|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Table 2 : MGMT promoter methylation and MSI test results. The results of the MGMT promoter methylation test and the Microsatellite instability test are shown for the 13 tumor samples that displayed defects in either of these two repair mechanisms. The first column indicates the patient sample ID and the second column indicates the tumor stage and histology of each sample. The copy number of the MGMT promoter amplicon is shown on the third column, while the copy number of the reference, β-Actin, amplicon in shown on the fourth column. The fifth column indicates whether the sample was categorized as having the MGMT promoter region methylated or unmethylated. Columns 6-11 show the instability of 6 microsatellite regions. Negative (Neg) indicates stable regions, MSI indicates regions that displayed instability, and LOH indicates regions with loss of heterozygosity. The last column indicates whether a sample was categorized as MSI-stable (MSIS) or samples with no regions of instability, MSI-high (MSIH) or samples were 2 loci or more exhibited microsatellite instability, or MSI-low(MSIL) or samples were 1 loci exhibited microsatellite instability. |